Thursday, July 2, 2020

University of Nottingham spin out secures major collaboration deal with Johnson and Johnson

Exonate Ltd has secured a major collaboration deal with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson for its ophthalmology program.

Exonate has been developing a new treatment for leading causes of blindness (diabetic retinopathy and age related macular degeneration).

Exonate Ltd was spun out of the University of Nottingham in 2013 by University of Nottingham academics, Prof David Bates and Prof Lucy Donaldson and Professor Steven Harper from the University of Bristol based on their intellectual property along with that of University of New South Wales’ Professor Jonathan Morris.

Through the collaboration, Exonate will work with Janssen Research & Development, and LLC scientists to develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.

Scientists at Exonate have developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. The agreement was facilitated by Johnson & Johnson Innovation.

The collaboration will fund the clinical trial and other activities in the company that will enable development of the first eye drop for treatment of diabetic macular oedema initially. The approach could transform the treatment of neovascular eye diseases, a market currently worth more than $6Bn a year, and extend it to preventative care too.

Exonate’s CEO, Dr Catherine Beech said: “I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases.”

Professor David Bates, the University of Nottingham, said: “This collaboration agreement allows Exonate to reach its primary goal of testing its designer compounds in patients for the first time.

“Over the last six years the team have worked immensely hard to develop key molecules that have the right safety, efficacy and delivery properties to be highly promising for patients.

“We will now be able to take that right through to clinical trial and beyond, in collaboration with one of the world’s largest pharmaceutical companies.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.






Latest news

CBILS loan helps Leicestershire logistics firm pay suppliers

Leicestershire headquartered logistics firm, Armstrong Logistics, has secured a six-figure finance package from HSBC UK through the Coronavirus Business Interruption Loan Scheme (CBILS). The funding...

CMA launches merger inquiry over Breedon’s CEMEX acquisition

The Competition and Markets Authority (CMA) has launched a merger inquiry into the anticipated acquisition by Breedon Group plc of certain assets of CEMEX. The...

Nottingham manufacturer wins major contract with Meggitt

Nottingham based Filtertechnik Ltd, a manufacturer and supplier of filtration solutions for oils and process fluids, has secured a major contract with Meggitt PLC,...

Derby firm offers support to Rolls-Royce workers with complimentary financial advice

Derby-based Glenrose Financial Planners has offered to support Rolls-Royce workers potentially affected by redundancy by providing complimentary one-to-one consultations to help them plan their...

Bulk materials testing resumes at the Wolfson Centre

If you have been experiencing bulk materials handling problems with your powders and/or bulk solids, you will be pleased to hear that the Wolfson...

Related news

Derby Redundancy Working Group appeals to firms recruiting engineering and manufacturing workers

A team launched to assist workers made redundant during the Coronavirus crisis is appealing for firms who are recruiting engineering and manufacturing skills into...

CBILS loan helps Leicestershire logistics firm pay suppliers

Leicestershire headquartered logistics firm, Armstrong Logistics, has secured a six-figure finance package from HSBC UK through the Coronavirus Business Interruption Loan Scheme (CBILS). The funding...

CMA launches merger inquiry over Breedon’s CEMEX acquisition

The Competition and Markets Authority (CMA) has launched a merger inquiry into the anticipated acquisition by Breedon Group plc of certain assets of CEMEX. The...

Nottingham manufacturer wins major contract with Meggitt

Nottingham based Filtertechnik Ltd, a manufacturer and supplier of filtration solutions for oils and process fluids, has secured a major contract with Meggitt PLC,...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close